fulvestrant,panitumumab
amgen,takeda
always enjoy hearing thoughts. here advocating for discussing options of maintenance and intermittent therapy with patients on egfr ab +chemo. maintenance panitumumab/5fulv improves pfs but has toxicity and has not been shown to increase os. #wcgic2022 
Gastrointestinal medical oncologist @clevelandclinic. Tweets are my own.